nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—Hypochromic anaemia—Octreotide—thymus cancer	0.0157	0.0261	CcSEcCtD
Thalidomide—Hernia—Octreotide—thymus cancer	0.013	0.0216	CcSEcCtD
Thalidomide—Sinus bradycardia—Octreotide—thymus cancer	0.0124	0.0206	CcSEcCtD
Thalidomide—FGFR2—neck—thymus cancer	0.0112	0.0505	CbGeAlD
Thalidomide—NFKB1—hematopoietic system—thymus cancer	0.0111	0.0501	CbGeAlD
Thalidomide—Hypothyroidism—Octreotide—thymus cancer	0.0095	0.0158	CcSEcCtD
Thalidomide—NFKB1—Canonical NF-kappaB pathway—CYLD—thymus cancer	0.00949	0.0541	CbGpPWpGaD
Thalidomide—Galactorrhoea—Octreotide—thymus cancer	0.00941	0.0156	CcSEcCtD
Thalidomide—Nail disorder—Octreotide—thymus cancer	0.00941	0.0156	CcSEcCtD
Thalidomide—CRBN—hematopoietic system—thymus cancer	0.0093	0.042	CbGeAlD
Thalidomide—Seborrhoeic dermatitis—Octreotide—thymus cancer	0.00895	0.0148	CcSEcCtD
Thalidomide—Menstrual disorder—Octreotide—thymus cancer	0.00895	0.0148	CcSEcCtD
Thalidomide—Intestinal obstruction—Octreotide—thymus cancer	0.00895	0.0148	CcSEcCtD
Thalidomide—Burning sensation—Octreotide—thymus cancer	0.00878	0.0146	CcSEcCtD
Thalidomide—Neuralgia—Octreotide—thymus cancer	0.00878	0.0146	CcSEcCtD
Thalidomide—Metrorrhagia—Octreotide—thymus cancer	0.00854	0.0142	CcSEcCtD
Thalidomide—NFKB1—cardiac atrium—thymus cancer	0.00843	0.038	CbGeAlD
Thalidomide—FGFR2—hematopoietic system—thymus cancer	0.00834	0.0376	CbGeAlD
Thalidomide—NFKB1—pituitary gland—thymus cancer	0.00823	0.0372	CbGeAlD
Thalidomide—Neuritis—Octreotide—thymus cancer	0.00817	0.0135	CcSEcCtD
Thalidomide—Cholestasis—Octreotide—thymus cancer	0.00803	0.0133	CcSEcCtD
Thalidomide—NFKB1—lymphoid tissue—thymus cancer	0.00781	0.0353	CbGeAlD
Thalidomide—TNF—lymph node—thymus cancer	0.00773	0.0349	CbGeAlD
Thalidomide—FGFR2—epithelium—thymus cancer	0.00762	0.0344	CbGeAlD
Thalidomide—Tingling sensation—Octreotide—thymus cancer	0.00759	0.0126	CcSEcCtD
Thalidomide—Petechiae—Octreotide—thymus cancer	0.00742	0.0123	CcSEcCtD
Thalidomide—Endocrine disorder—Octreotide—thymus cancer	0.00736	0.0122	CcSEcCtD
Thalidomide—Numbness—Octreotide—thymus cancer	0.00736	0.0122	CcSEcCtD
Thalidomide—Acne—Octreotide—thymus cancer	0.00725	0.012	CcSEcCtD
Thalidomide—TNF—Canonical NF-kappaB pathway—CYLD—thymus cancer	0.00723	0.0413	CbGpPWpGaD
Thalidomide—NFKB1—bone marrow—thymus cancer	0.00712	0.0321	CbGeAlD
Thalidomide—NFKB1—thyroid gland—thymus cancer	0.0071	0.032	CbGeAlD
Thalidomide—CRBN—cardiac atrium—thymus cancer	0.00706	0.0319	CbGeAlD
Thalidomide—Sensory loss—Octreotide—thymus cancer	0.00704	0.0117	CcSEcCtD
Thalidomide—Amenorrhoea—Octreotide—thymus cancer	0.00694	0.0115	CcSEcCtD
Thalidomide—Jaundice cholestatic—Octreotide—thymus cancer	0.00694	0.0115	CcSEcCtD
Thalidomide—CRBN—pituitary gland—thymus cancer	0.0069	0.0311	CbGeAlD
Thalidomide—Viral infection—Octreotide—thymus cancer	0.00676	0.0112	CcSEcCtD
Thalidomide—Hyperbilirubinaemia—Octreotide—thymus cancer	0.00671	0.0111	CcSEcCtD
Thalidomide—Cellulitis—Octreotide—thymus cancer	0.00671	0.0111	CcSEcCtD
Thalidomide—Arthropathy—Octreotide—thymus cancer	0.00671	0.0111	CcSEcCtD
Thalidomide—Herpes simplex—Octreotide—thymus cancer	0.00662	0.011	CcSEcCtD
Thalidomide—Drug interaction—Octreotide—thymus cancer	0.00658	0.0109	CcSEcCtD
Thalidomide—CRBN—lymphoid tissue—thymus cancer	0.00655	0.0296	CbGeAlD
Thalidomide—NFKB1—lung—thymus cancer	0.00645	0.0291	CbGeAlD
Thalidomide—Hearing impaired—Octreotide—thymus cancer	0.00641	0.0106	CcSEcCtD
Thalidomide—Phosphatase alkaline increased—Octreotide—thymus cancer	0.0061	0.0101	CcSEcCtD
Thalidomide—Hyperkalaemia—Octreotide—thymus cancer	0.00599	0.00994	CcSEcCtD
Thalidomide—Eructation—Octreotide—thymus cancer	0.00599	0.00994	CcSEcCtD
Thalidomide—CRBN—bone marrow—thymus cancer	0.00596	0.0269	CbGeAlD
Thalidomide—CRBN—thyroid gland—thymus cancer	0.00595	0.0269	CbGeAlD
Thalidomide—Candida infection—Octreotide—thymus cancer	0.00583	0.00966	CcSEcCtD
Thalidomide—Neuropathy—Octreotide—thymus cancer	0.00573	0.0095	CcSEcCtD
Thalidomide—Cramps of lower extremities—Octreotide—thymus cancer	0.00561	0.00929	CcSEcCtD
Thalidomide—Gynaecomastia—Octreotide—thymus cancer	0.00546	0.00905	CcSEcCtD
Thalidomide—NFKB1—TNF receptor signaling pathway —CYLD—thymus cancer	0.00545	0.0311	CbGpPWpGaD
Thalidomide—CRBN—lung—thymus cancer	0.0054	0.0244	CbGeAlD
Thalidomide—FGFR2—thyroid gland—thymus cancer	0.00533	0.0241	CbGeAlD
Thalidomide—Hyperkinesia—Octreotide—thymus cancer	0.00532	0.00882	CcSEcCtD
Thalidomide—Thrombophlebitis—Octreotide—thymus cancer	0.00512	0.00848	CcSEcCtD
Thalidomide—NFKB1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CYLD—thymus cancer	0.0051	0.0291	CbGpPWpGaD
Thalidomide—Blood alkaline phosphatase increased—Octreotide—thymus cancer	0.00509	0.00844	CcSEcCtD
Thalidomide—Diabetes mellitus—Octreotide—thymus cancer	0.00509	0.00844	CcSEcCtD
Thalidomide—Gastroenteritis—Octreotide—thymus cancer	0.005	0.00828	CcSEcCtD
Thalidomide—Deafness—Octreotide—thymus cancer	0.00495	0.00821	CcSEcCtD
Thalidomide—Cardiac failure congestive—Octreotide—thymus cancer	0.00488	0.0081	CcSEcCtD
Thalidomide—FGFR2—lung—thymus cancer	0.00484	0.0219	CbGeAlD
Thalidomide—Injury—Octreotide—thymus cancer	0.00482	0.00799	CcSEcCtD
Thalidomide—Amnesia—Octreotide—thymus cancer	0.00471	0.00781	CcSEcCtD
Thalidomide—Visual disturbance—Octreotide—thymus cancer	0.00467	0.00775	CcSEcCtD
Thalidomide—Arthritis—Octreotide—thymus cancer	0.00456	0.00755	CcSEcCtD
Thalidomide—Hypoglycaemia—Octreotide—thymus cancer	0.00454	0.00752	CcSEcCtD
Thalidomide—Pain in extremity—Octreotide—thymus cancer	0.00443	0.00734	CcSEcCtD
Thalidomide—Osteoarthritis—Octreotide—thymus cancer	0.00443	0.00734	CcSEcCtD
Thalidomide—Gastrointestinal haemorrhage—Octreotide—thymus cancer	0.00443	0.00734	CcSEcCtD
Thalidomide—NFKB1—lymph node—thymus cancer	0.00441	0.0199	CbGeAlD
Thalidomide—Psychotic disorder—Octreotide—thymus cancer	0.00433	0.00717	CcSEcCtD
Thalidomide—TNF—TNF receptor signaling pathway —CYLD—thymus cancer	0.00415	0.0237	CbGpPWpGaD
Thalidomide—Dehydration—Octreotide—thymus cancer	0.00412	0.00683	CcSEcCtD
Thalidomide—Dry skin—Octreotide—thymus cancer	0.00406	0.00673	CcSEcCtD
Thalidomide—Cramp muscle—Octreotide—thymus cancer	0.00399	0.00661	CcSEcCtD
Thalidomide—Muscular weakness—Octreotide—thymus cancer	0.00391	0.00648	CcSEcCtD
Thalidomide—Abdominal distension—Octreotide—thymus cancer	0.00385	0.00639	CcSEcCtD
Thalidomide—NFKB1—T-Cell Receptor and Co-stimulatory Signaling—CD8A—thymus cancer	0.00385	0.022	CbGpPWpGaD
Thalidomide—Influenza—Octreotide—thymus cancer	0.00383	0.00635	CcSEcCtD
Thalidomide—Bronchospasm—Octreotide—thymus cancer	0.00377	0.00624	CcSEcCtD
Thalidomide—Pancreatitis—Octreotide—thymus cancer	0.00375	0.00622	CcSEcCtD
Thalidomide—CYP2C19—hematopoietic system—thymus cancer	0.00374	0.0169	CbGeAlD
Thalidomide—CRBN—lymph node—thymus cancer	0.0037	0.0167	CbGeAlD
Thalidomide—Bronchitis—Octreotide—thymus cancer	0.00368	0.0061	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Octreotide—thymus cancer	0.00356	0.0059	CcSEcCtD
Thalidomide—Pollakiuria—Octreotide—thymus cancer	0.00354	0.00586	CcSEcCtD
Thalidomide—NFKB1—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—CYLD—thymus cancer	0.0035	0.02	CbGpPWpGaD
Thalidomide—Weight increased—Octreotide—thymus cancer	0.00348	0.00578	CcSEcCtD
Thalidomide—Weight decreased—Octreotide—thymus cancer	0.00346	0.00574	CcSEcCtD
Thalidomide—NFKB1—Notch Signaling Pathway—MAML2—thymus cancer	0.00345	0.0197	CbGpPWpGaD
Thalidomide—Hyperglycaemia—Octreotide—thymus cancer	0.00345	0.00572	CcSEcCtD
Thalidomide—Pneumonia—Octreotide—thymus cancer	0.00343	0.00569	CcSEcCtD
Thalidomide—Drowsiness—Octreotide—thymus cancer	0.00341	0.00566	CcSEcCtD
Thalidomide—Depression—Octreotide—thymus cancer	0.0034	0.00564	CcSEcCtD
Thalidomide—Neuropathy peripheral—Octreotide—thymus cancer	0.00335	0.00555	CcSEcCtD
Thalidomide—Conjunctivitis—Octreotide—thymus cancer	0.00332	0.0055	CcSEcCtD
Thalidomide—Haematuria—Octreotide—thymus cancer	0.00325	0.00539	CcSEcCtD
Thalidomide—Epistaxis—Octreotide—thymus cancer	0.00322	0.00534	CcSEcCtD
Thalidomide—Sinusitis—Octreotide—thymus cancer	0.0032	0.00531	CcSEcCtD
Thalidomide—Bradycardia—Octreotide—thymus cancer	0.00312	0.00517	CcSEcCtD
Thalidomide—NFKB1—TFs Regulate miRNAs related to cardiac hypertrophy—AKT1—thymus cancer	0.00309	0.0176	CbGpPWpGaD
Thalidomide—Rhinitis—Octreotide—thymus cancer	0.00307	0.00509	CcSEcCtD
Thalidomide—Hepatitis—Octreotide—thymus cancer	0.00306	0.00508	CcSEcCtD
Thalidomide—CYP1A2—hematopoietic system—thymus cancer	0.00306	0.0138	CbGeAlD
Thalidomide—Hypoaesthesia—Octreotide—thymus cancer	0.00305	0.00505	CcSEcCtD
Thalidomide—Pharyngitis—Octreotide—thymus cancer	0.00304	0.00504	CcSEcCtD
Thalidomide—Oedema peripheral—Octreotide—thymus cancer	0.00302	0.005	CcSEcCtD
Thalidomide—CYP1A1—hematopoietic system—thymus cancer	0.00302	0.0136	CbGeAlD
Thalidomide—Visual impairment—Octreotide—thymus cancer	0.00295	0.0049	CcSEcCtD
Thalidomide—CYP3A5—hematopoietic system—thymus cancer	0.00295	0.0133	CbGeAlD
Thalidomide—CYP2C9—hematopoietic system—thymus cancer	0.0029	0.0131	CbGeAlD
Thalidomide—Tinnitus—Octreotide—thymus cancer	0.00286	0.00474	CcSEcCtD
Thalidomide—Cardiac disorder—Octreotide—thymus cancer	0.00284	0.00471	CcSEcCtD
Thalidomide—Immune system disorder—Octreotide—thymus cancer	0.00277	0.00459	CcSEcCtD
Thalidomide—CYP1A1—epithelium—thymus cancer	0.00276	0.0124	CbGeAlD
Thalidomide—CYP2E1—hematopoietic system—thymus cancer	0.00275	0.0124	CbGeAlD
Thalidomide—Arrhythmia—Octreotide—thymus cancer	0.00274	0.00454	CcSEcCtD
Thalidomide—Alopecia—Octreotide—thymus cancer	0.00271	0.00449	CcSEcCtD
Thalidomide—Mental disorder—Octreotide—thymus cancer	0.00268	0.00445	CcSEcCtD
Thalidomide—Malnutrition—Octreotide—thymus cancer	0.00267	0.00442	CcSEcCtD
Thalidomide—PTGS1—hematopoietic system—thymus cancer	0.00265	0.012	CbGeAlD
Thalidomide—Flatulence—Octreotide—thymus cancer	0.00263	0.00436	CcSEcCtD
Thalidomide—Tension—Octreotide—thymus cancer	0.00262	0.00434	CcSEcCtD
Thalidomide—Nervousness—Octreotide—thymus cancer	0.00259	0.00429	CcSEcCtD
Thalidomide—Back pain—Octreotide—thymus cancer	0.00258	0.00428	CcSEcCtD
Thalidomide—Muscle spasms—Octreotide—thymus cancer	0.00256	0.00425	CcSEcCtD
Thalidomide—PTGS2—hematopoietic system—thymus cancer	0.00253	0.0114	CbGeAlD
Thalidomide—Vision blurred—Octreotide—thymus cancer	0.00251	0.00417	CcSEcCtD
Thalidomide—Tremor—Octreotide—thymus cancer	0.0025	0.00414	CcSEcCtD
Thalidomide—Ill-defined disorder—Octreotide—thymus cancer	0.00247	0.0041	CcSEcCtD
Thalidomide—Anaemia—Octreotide—thymus cancer	0.00247	0.00409	CcSEcCtD
Thalidomide—Agitation—Octreotide—thymus cancer	0.00245	0.00406	CcSEcCtD
Thalidomide—PTGS1—epithelium—thymus cancer	0.00242	0.0109	CbGeAlD
Thalidomide—Malaise—Octreotide—thymus cancer	0.00241	0.00399	CcSEcCtD
Thalidomide—Vertigo—Octreotide—thymus cancer	0.0024	0.00397	CcSEcCtD
Thalidomide—Syncope—Octreotide—thymus cancer	0.00239	0.00397	CcSEcCtD
Thalidomide—Palpitations—Octreotide—thymus cancer	0.00236	0.00391	CcSEcCtD
Thalidomide—Loss of consciousness—Octreotide—thymus cancer	0.00234	0.00389	CcSEcCtD
Thalidomide—Cough—Octreotide—thymus cancer	0.00233	0.00386	CcSEcCtD
Thalidomide—PTGS2—epithelium—thymus cancer	0.00232	0.0105	CbGeAlD
Thalidomide—Convulsion—Octreotide—thymus cancer	0.00231	0.00383	CcSEcCtD
Thalidomide—Hypertension—Octreotide—thymus cancer	0.0023	0.00382	CcSEcCtD
Thalidomide—CYP1A1—cardiac atrium—thymus cancer	0.00229	0.0103	CbGeAlD
Thalidomide—Myalgia—Octreotide—thymus cancer	0.00227	0.00376	CcSEcCtD
Thalidomide—Chest pain—Octreotide—thymus cancer	0.00227	0.00376	CcSEcCtD
Thalidomide—Arthralgia—Octreotide—thymus cancer	0.00227	0.00376	CcSEcCtD
Thalidomide—Anxiety—Octreotide—thymus cancer	0.00226	0.00375	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.00226	0.00374	CcSEcCtD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—CYLD—thymus cancer	0.00225	0.0128	CbGpPWpGaD
Thalidomide—Discomfort—Octreotide—thymus cancer	0.00224	0.00372	CcSEcCtD
Thalidomide—Dry mouth—Octreotide—thymus cancer	0.00222	0.00368	CcSEcCtD
Thalidomide—Oedema—Octreotide—thymus cancer	0.00218	0.00361	CcSEcCtD
Thalidomide—Infection—Octreotide—thymus cancer	0.00216	0.00359	CcSEcCtD
Thalidomide—NFKB1—IL12-mediated signaling events—CD8A—thymus cancer	0.00215	0.0123	CbGpPWpGaD
Thalidomide—Shock—Octreotide—thymus cancer	0.00214	0.00355	CcSEcCtD
Thalidomide—Nervous system disorder—Octreotide—thymus cancer	0.00213	0.00354	CcSEcCtD
Thalidomide—Thrombocytopenia—Octreotide—thymus cancer	0.00213	0.00353	CcSEcCtD
Thalidomide—Tachycardia—Octreotide—thymus cancer	0.00212	0.00352	CcSEcCtD
Thalidomide—Skin disorder—Octreotide—thymus cancer	0.00211	0.00351	CcSEcCtD
Thalidomide—Hyperhidrosis—Octreotide—thymus cancer	0.0021	0.00349	CcSEcCtD
Thalidomide—Anorexia—Octreotide—thymus cancer	0.00207	0.00344	CcSEcCtD
Thalidomide—NFKB1—T-Cell Receptor and Co-stimulatory Signaling—IL2—thymus cancer	0.00203	0.0116	CbGpPWpGaD
Thalidomide—PTGS1—cardiac atrium—thymus cancer	0.00201	0.00908	CbGeAlD
Thalidomide—Musculoskeletal discomfort—Octreotide—thymus cancer	0.00198	0.00329	CcSEcCtD
Thalidomide—Insomnia—Octreotide—thymus cancer	0.00197	0.00326	CcSEcCtD
Thalidomide—PTGS1—pituitary gland—thymus cancer	0.00197	0.00887	CbGeAlD
Thalidomide—NFKB1—Developmental Biology—DPYSL5—thymus cancer	0.00196	0.0112	CbGpPWpGaD
Thalidomide—CYP1A2—thyroid gland—thymus cancer	0.00196	0.00883	CbGeAlD
Thalidomide—Paraesthesia—Octreotide—thymus cancer	0.00195	0.00324	CcSEcCtD
Thalidomide—Dyspnoea—Octreotide—thymus cancer	0.00194	0.00322	CcSEcCtD
Thalidomide—CYP2E1—lymphoid tissue—thymus cancer	0.00194	0.00874	CbGeAlD
Thalidomide—Somnolence—Octreotide—thymus cancer	0.00194	0.00321	CcSEcCtD
Thalidomide—CYP1A1—thyroid gland—thymus cancer	0.00193	0.00871	CbGeAlD
Thalidomide—Dyspepsia—Octreotide—thymus cancer	0.00192	0.00318	CcSEcCtD
Thalidomide—Decreased appetite—Octreotide—thymus cancer	0.00189	0.00314	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Octreotide—thymus cancer	0.00188	0.00312	CcSEcCtD
Thalidomide—PTGS2—pituitary gland—thymus cancer	0.00188	0.00848	CbGeAlD
Thalidomide—Fatigue—Octreotide—thymus cancer	0.00188	0.00311	CcSEcCtD
Thalidomide—Pain—Octreotide—thymus cancer	0.00186	0.00309	CcSEcCtD
Thalidomide—Constipation—Octreotide—thymus cancer	0.00186	0.00309	CcSEcCtD
Thalidomide—NFKB1—IL23-mediated signaling events—CD4—thymus cancer	0.00182	0.0104	CbGpPWpGaD
Thalidomide—Feeling abnormal—Octreotide—thymus cancer	0.00179	0.00297	CcSEcCtD
Thalidomide—TNF—Cytokines and Inflammatory Response—CD4—thymus cancer	0.00178	0.0102	CbGpPWpGaD
Thalidomide—PTGS2—lymphoid tissue—thymus cancer	0.00178	0.00805	CbGeAlD
Thalidomide—Gastrointestinal pain—Octreotide—thymus cancer	0.00178	0.00295	CcSEcCtD
Thalidomide—CYP1A2—lung—thymus cancer	0.00178	0.00802	CbGeAlD
Thalidomide—CYP2E1—thyroid gland—thymus cancer	0.00176	0.00794	CbGeAlD
Thalidomide—CYP1A1—lung—thymus cancer	0.00175	0.00791	CbGeAlD
Thalidomide—Urticaria—Octreotide—thymus cancer	0.00173	0.00287	CcSEcCtD
Thalidomide—Abdominal pain—Octreotide—thymus cancer	0.00172	0.00285	CcSEcCtD
Thalidomide—Body temperature increased—Octreotide—thymus cancer	0.00172	0.00285	CcSEcCtD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—CYLD—thymus cancer	0.00171	0.00978	CbGpPWpGaD
Thalidomide—CYP3A5—lung—thymus cancer	0.00171	0.00773	CbGeAlD
Thalidomide—PTGS1—thyroid gland—thymus cancer	0.00169	0.00765	CbGeAlD
Thalidomide—TNF—IL27-mediated signaling events—IL2—thymus cancer	0.00169	0.00965	CbGpPWpGaD
Thalidomide—NFKB1—Downstream TCR signaling—CD4—thymus cancer	0.00168	0.00956	CbGpPWpGaD
Thalidomide—NFKB1—IL2 signaling events mediated by PI3K—IL2—thymus cancer	0.00167	0.00955	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—IL2—thymus cancer	0.00167	0.00955	CbGpPWpGaD
Thalidomide—TNF—Cytokines and Inflammatory Response—IL2—thymus cancer	0.00164	0.00936	CbGpPWpGaD
Thalidomide—PTGS2—bone marrow—thymus cancer	0.00162	0.00733	CbGeAlD
Thalidomide—Hypersensitivity—Octreotide—thymus cancer	0.0016	0.00266	CcSEcCtD
Thalidomide—CYP2E1—lung—thymus cancer	0.0016	0.00721	CbGeAlD
Thalidomide—Asthenia—Octreotide—thymus cancer	0.00156	0.00259	CcSEcCtD
Thalidomide—NFKB1—TCR Signaling Pathway—CD8A—thymus cancer	0.00156	0.00888	CbGpPWpGaD
Thalidomide—Pruritus—Octreotide—thymus cancer	0.00154	0.00255	CcSEcCtD
Thalidomide—PTGS1—lung—thymus cancer	0.00154	0.00695	CbGeAlD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—CD8A—thymus cancer	0.00152	0.00867	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—DPYSL5—thymus cancer	0.0015	0.00854	CbGpPWpGaD
Thalidomide—Diarrhoea—Octreotide—thymus cancer	0.00149	0.00247	CcSEcCtD
Thalidomide—PTGS2—lung—thymus cancer	0.00147	0.00664	CbGeAlD
Thalidomide—Dizziness—Octreotide—thymus cancer	0.00144	0.00239	CcSEcCtD
Thalidomide—TNF—IL23-mediated signaling events—CD4—thymus cancer	0.00139	0.00791	CbGpPWpGaD
Thalidomide—Vomiting—Octreotide—thymus cancer	0.00138	0.00229	CcSEcCtD
Thalidomide—Rash—Octreotide—thymus cancer	0.00137	0.00228	CcSEcCtD
Thalidomide—Dermatitis—Octreotide—thymus cancer	0.00137	0.00227	CcSEcCtD
Thalidomide—Headache—Octreotide—thymus cancer	0.00136	0.00226	CcSEcCtD
Thalidomide—NFKB1—Estrogen signaling pathway—AKT1—thymus cancer	0.00133	0.00758	CbGpPWpGaD
Thalidomide—Nausea—Octreotide—thymus cancer	0.00129	0.00214	CcSEcCtD
Thalidomide—TNF—IL23-mediated signaling events—IL2—thymus cancer	0.00128	0.00728	CbGpPWpGaD
Thalidomide—NFKB1—TCR signaling—CD4—thymus cancer	0.00125	0.00715	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—CD4—thymus cancer	0.00124	0.00705	CbGpPWpGaD
Thalidomide—FGFR2—Angiogenesis—AKT1—thymus cancer	0.00122	0.00695	CbGpPWpGaD
Thalidomide—CYP1A1—lymph node—thymus cancer	0.0012	0.00541	CbGeAlD
Thalidomide—FGFR2—Constitutive PI3K/AKT Signaling in Cancer—KIT—thymus cancer	0.00115	0.00656	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—IL2—thymus cancer	0.00114	0.00649	CbGpPWpGaD
Thalidomide—NFKB1—T-Cell Receptor and Co-stimulatory Signaling—AKT1—thymus cancer	0.0011	0.00629	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL2—thymus cancer	0.00107	0.00611	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—IL2—thymus cancer	0.00105	0.00601	CbGpPWpGaD
Thalidomide—PTGS1—lymph node—thymus cancer	0.00105	0.00475	CbGeAlD
Thalidomide—NFKB1—IL17 signaling pathway—AKT1—thymus cancer	0.00105	0.00597	CbGpPWpGaD
Thalidomide—FGFR2—PI-3K cascade—KIT—thymus cancer	0.00104	0.00591	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of Telomerase—IL2—thymus cancer	0.00103	0.00587	CbGpPWpGaD
Thalidomide—FGFR2—PI3K/AKT activation—KIT—thymus cancer	0.00101	0.00577	CbGpPWpGaD
Thalidomide—PTGS2—lymph node—thymus cancer	0.00101	0.00454	CbGeAlD
Thalidomide—FGFR2—GAB1 signalosome—KIT—thymus cancer	0.001	0.00572	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—CDKN2A—thymus cancer	0.001	0.00572	CbGpPWpGaD
Thalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—thymus cancer	0.001	0.00572	CbGpPWpGaD
Thalidomide—FGFR2—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—thymus cancer	0.00098	0.00559	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—CDKN2A—thymus cancer	0.00097	0.00553	CbGpPWpGaD
Thalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—thymus cancer	0.000959	0.00547	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—CDKN2A—thymus cancer	0.00094	0.00537	CbGpPWpGaD
Thalidomide—NFKB1—CD40/CD40L signaling—AKT1—thymus cancer	0.000928	0.00529	CbGpPWpGaD
Thalidomide—NFKB1—IL2 signaling events mediated by PI3K—AKT1—thymus cancer	0.000908	0.00518	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—CD4—thymus cancer	0.000893	0.0051	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—IL2—thymus cancer	0.000886	0.00505	CbGpPWpGaD
Thalidomide—NFKB1—Senescence-Associated Secretory Phenotype (SASP)—CDKN2A—thymus cancer	0.000839	0.00478	CbGpPWpGaD
Thalidomide—NFKB1—TWEAK Signaling Pathway—AKT1—thymus cancer	0.00082	0.00468	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—CDKN2A—thymus cancer	0.000814	0.00464	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—IL2—thymus cancer	0.000808	0.00461	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—IL2—thymus cancer	0.000803	0.00458	CbGpPWpGaD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2—thymus cancer	0.000803	0.00458	CbGpPWpGaD
Thalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—thymus cancer	0.000802	0.00457	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—KIT—thymus cancer	0.000774	0.00442	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—CDKN2A—thymus cancer	0.000764	0.00436	CbGpPWpGaD
Thalidomide—NFKB1—TSLP Signaling Pathway—AKT1—thymus cancer	0.00075	0.00428	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—KIT—thymus cancer	0.000741	0.00423	CbGpPWpGaD
Thalidomide—NFKB1—Ceramide signaling pathway—AKT1—thymus cancer	0.000737	0.00421	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—KIT—thymus cancer	0.000729	0.00416	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CYLD—thymus cancer	0.00072	0.00411	CbGpPWpGaD
Thalidomide—NFKB1—Angiopoietin receptor Tie2-mediated signaling—AKT1—thymus cancer	0.000713	0.00407	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—KIT—thymus cancer	0.000712	0.00407	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—IL2—thymus cancer	0.000711	0.00405	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—KIT—thymus cancer	0.000696	0.00397	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL2—thymus cancer	0.000695	0.00397	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—KIT—thymus cancer	0.000693	0.00395	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—KIT—thymus cancer	0.000689	0.00393	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—KIT—thymus cancer	0.000686	0.00391	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—TP53—thymus cancer	0.000685	0.00391	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CYLD—thymus cancer	0.000684	0.0039	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—thymus cancer	0.000681	0.00389	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—KIT—thymus cancer	0.00068	0.00388	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—TP53—thymus cancer	0.000677	0.00386	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—KIT—thymus cancer	0.000676	0.00386	CbGpPWpGaD
Thalidomide—NFKB1—IL-4 Signaling Pathway—AKT1—thymus cancer	0.000671	0.00383	CbGpPWpGaD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—TP53—thymus cancer	0.000668	0.00381	CbGpPWpGaD
Thalidomide—NFKB1—RANKL/RANK Signaling Pathway—AKT1—thymus cancer	0.000661	0.00377	CbGpPWpGaD
Thalidomide—NFKB1—Cardiac Hypertrophic Response—AKT1—thymus cancer	0.000661	0.00377	CbGpPWpGaD
Thalidomide—NFKB1—IL-1 signaling pathway—AKT1—thymus cancer	0.000661	0.00377	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—KIT—thymus cancer	0.000645	0.00368	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—KIT—thymus cancer	0.000645	0.00368	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—KIT—thymus cancer	0.000645	0.00368	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—KIT—thymus cancer	0.000639	0.00365	CbGpPWpGaD
Thalidomide—FGFR2—FGF signaling pathway—AKT1—thymus cancer	0.000636	0.00363	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—KIT—thymus cancer	0.000634	0.00362	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—KIT—thymus cancer	0.000631	0.0036	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—KIT—thymus cancer	0.000629	0.00359	CbGpPWpGaD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—AKT1—thymus cancer	0.000627	0.00358	CbGpPWpGaD
Thalidomide—TNF—TWEAK Signaling Pathway—AKT1—thymus cancer	0.000625	0.00357	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—thymus cancer	0.00062	0.00354	CbGpPWpGaD
Thalidomide—NFKB1—Fc-epsilon receptor I signaling in mast cells—AKT1—thymus cancer	0.000608	0.00347	CbGpPWpGaD
Thalidomide—NFKB1—Notch Signaling Pathway—AKT1—thymus cancer	0.000608	0.00347	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—KIT—thymus cancer	0.000597	0.00341	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—thymus cancer	0.000588	0.00336	CbGpPWpGaD
Thalidomide—NFKB1—LPA receptor mediated events—AKT1—thymus cancer	0.000586	0.00334	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—KIT—thymus cancer	0.000582	0.00332	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—AKT1—thymus cancer	0.000578	0.0033	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—KIT—thymus cancer	0.000571	0.00326	CbGpPWpGaD
Thalidomide—NFKB1—AGE/RAGE pathway—AKT1—thymus cancer	0.000571	0.00326	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—TP53—thymus cancer	0.000569	0.00325	CbGpPWpGaD
Thalidomide—NFKB1—BCR signaling pathway—AKT1—thymus cancer	0.000564	0.00322	CbGpPWpGaD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—AKT1—thymus cancer	0.000564	0.00322	CbGpPWpGaD
Thalidomide—TNF—Ceramide signaling pathway—AKT1—thymus cancer	0.000562	0.0032	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TP53—thymus cancer	0.000558	0.00318	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of Telomerase—AKT1—thymus cancer	0.000558	0.00318	CbGpPWpGaD
Thalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—AKT1—thymus cancer	0.000544	0.0031	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—TP53—thymus cancer	0.00054	0.00308	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—CDKN2A—thymus cancer	0.000531	0.00303	CbGpPWpGaD
Thalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thymus cancer	0.00053	0.00302	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—TP53—thymus cancer	0.000523	0.00299	CbGpPWpGaD
Thalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—thymus cancer	0.000519	0.00296	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—AKT1—thymus cancer	0.000516	0.00294	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—TP53—thymus cancer	0.000515	0.00294	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—IL2—thymus cancer	0.000504	0.00288	CbGpPWpGaD
Thalidomide—TNF—Cardiac Hypertrophic Response—AKT1—thymus cancer	0.000504	0.00287	CbGpPWpGaD
Thalidomide—TNF—Caspase Cascade in Apoptosis—AKT1—thymus cancer	0.000489	0.00279	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—AKT1—thymus cancer	0.00048	0.00274	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—thymus cancer	0.000472	0.0027	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thymus cancer	0.000471	0.00269	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—AKT1—thymus cancer	0.000471	0.00269	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—KIT—thymus cancer	0.000463	0.00264	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—AKT1—thymus cancer	0.000456	0.0026	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—TP53—thymus cancer	0.000453	0.00258	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thymus cancer	0.000447	0.00255	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—TP53—thymus cancer	0.000446	0.00255	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—AKT1—thymus cancer	0.000446	0.00254	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—CD4—thymus cancer	0.000445	0.00254	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—KIT—thymus cancer	0.00044	0.00251	CbGpPWpGaD
Thalidomide—FGFR2—Constitutive PI3K/AKT Signaling in Cancer—AKT1—thymus cancer	0.000439	0.0025	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—AKT1—thymus cancer	0.000438	0.0025	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—AKT1—thymus cancer	0.000438	0.0025	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—thymus cancer	0.000425	0.00243	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Receptor Signaling Pathway—AKT1—thymus cancer	0.00042	0.0024	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CYLD—thymus cancer	0.00042	0.00239	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—AKT1—thymus cancer	0.000403	0.0023	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—CDKN2A—thymus cancer	0.000401	0.00229	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CYLD—thymus cancer	0.000398	0.00227	CbGpPWpGaD
Thalidomide—FGFR2—PI-3K cascade—AKT1—thymus cancer	0.000395	0.00225	CbGpPWpGaD
Thalidomide—FGFR2—PI3K/AKT activation—AKT1—thymus cancer	0.000386	0.0022	CbGpPWpGaD
Thalidomide—FGFR2—GAB1 signalosome—AKT1—thymus cancer	0.000383	0.00218	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—AKT1—thymus cancer	0.000382	0.00218	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—thymus cancer	0.000375	0.00214	CbGpPWpGaD
Thalidomide—FGFR2—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thymus cancer	0.000374	0.00213	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—AKT1—thymus cancer	0.000359	0.00205	CbGpPWpGaD
Thalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thymus cancer	0.000359	0.00205	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—TP53—thymus cancer	0.000349	0.00199	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD8A—thymus cancer	0.000338	0.00193	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—AKT1—thymus cancer	0.000334	0.0019	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL2—thymus cancer	0.000332	0.00189	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—TP53—thymus cancer	0.000324	0.00185	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD8A—thymus cancer	0.000321	0.00183	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—thymus cancer	0.00032	0.00183	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—AKT1—thymus cancer	0.000315	0.0018	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL2—thymus cancer	0.000312	0.00178	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—AKT1—thymus cancer	0.000307	0.00175	CbGpPWpGaD
Thalidomide—NFKB1—BDNF signaling pathway—AKT1—thymus cancer	0.000306	0.00175	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—thymus cancer	0.000295	0.00169	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—AKT1—thymus cancer	0.000295	0.00169	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—AKT1—thymus cancer	0.000295	0.00168	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAML2—thymus cancer	0.000292	0.00167	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	0.000289	0.00165	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—AKT1—thymus cancer	0.000283	0.00161	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—AKT1—thymus cancer	0.000278	0.00159	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	0.000272	0.00155	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—AKT1—thymus cancer	0.000271	0.00154	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—AKT1—thymus cancer	0.000266	0.00152	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—AKT1—thymus cancer	0.000264	0.00151	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KIT—thymus cancer	0.000264	0.00151	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—AKT1—thymus cancer	0.000263	0.0015	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—AKT1—thymus cancer	0.000262	0.00149	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—thymus cancer	0.00026	0.00149	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	0.000259	0.00148	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	0.000258	0.00147	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KIT—thymus cancer	0.000254	0.00145	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KIT—thymus cancer	0.000251	0.00143	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—AKT1—thymus cancer	0.000246	0.00141	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	0.000246	0.00141	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—AKT1—thymus cancer	0.000246	0.00141	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	0.000244	0.00139	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—thymus cancer	0.000244	0.00139	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—AKT1—thymus cancer	0.000244	0.00139	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—AKT1—thymus cancer	0.000242	0.00138	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—AKT1—thymus cancer	0.000241	0.00137	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KIT—thymus cancer	0.000241	0.00137	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—AKT1—thymus cancer	0.00024	0.00137	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—AKT1—thymus cancer	0.00024	0.00137	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—AKT1—thymus cancer	0.000228	0.0013	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—thymus cancer	0.000223	0.00127	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	0.00022	0.00126	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—AKT1—thymus cancer	0.00022	0.00125	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	0.000218	0.00124	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAML2—thymus cancer	0.000216	0.00123	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—AKT1—thymus cancer	0.000206	0.00118	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD8A—thymus cancer	0.000205	0.00117	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAML2—thymus cancer	0.000205	0.00117	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CD4—thymus cancer	0.000202	0.00115	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—thymus cancer	0.0002	0.00114	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD8A—thymus cancer	0.000194	0.00111	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD4—thymus cancer	0.000194	0.00111	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CD4—thymus cancer	0.000192	0.00109	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	0.000186	0.00106	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD4—thymus cancer	0.000184	0.00105	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—AKT1—thymus cancer	0.000177	0.00101	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—AKT1—thymus cancer	0.000168	0.000957	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KIT—thymus cancer	0.000154	0.000878	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KIT—thymus cancer	0.000146	0.000833	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAML2—thymus cancer	0.000145	0.000828	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	0.000136	0.000777	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KIT—thymus cancer	0.000135	0.000769	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD4—thymus cancer	0.000118	0.000672	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	0.000115	0.000657	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—AKT1—thymus cancer	0.000114	0.000651	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD4—thymus cancer	0.000112	0.000637	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2—thymus cancer	0.000108	0.000618	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD4—thymus cancer	0.000103	0.000588	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2—thymus cancer	0.000103	0.000586	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—AKT1—thymus cancer	0.000101	0.000575	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KIT—thymus cancer	9.95e-05	0.000568	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—AKT1—thymus cancer	9.68e-05	0.000552	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—AKT1—thymus cancer	9.57e-05	0.000546	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KIT—thymus cancer	9.44e-05	0.000539	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—AKT1—thymus cancer	9.19e-05	0.000524	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—thymus cancer	8.7e-05	0.000496	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—thymus cancer	7e-05	0.0004	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KIT—thymus cancer	6.7e-05	0.000382	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—thymus cancer	6.64e-05	0.000379	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—thymus cancer	5.87e-05	0.000335	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—thymus cancer	5.57e-05	0.000318	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—thymus cancer	5.14e-05	0.000294	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—thymus cancer	5.12e-05	0.000292	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—thymus cancer	4.5e-05	0.000257	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—thymus cancer	4.27e-05	0.000243	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—thymus cancer	3.8e-05	0.000217	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—thymus cancer	3.6e-05	0.000206	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—thymus cancer	2.7e-05	0.000154	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—thymus cancer	2.55e-05	0.000146	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—thymus cancer	2.14e-05	0.000122	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—thymus cancer	2.01e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—thymus cancer	2.01e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—thymus cancer	1.9e-05	0.000108	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—thymus cancer	1.55e-05	8.87e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—thymus cancer	1.42e-05	8.09e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—thymus cancer	1.21e-05	6.91e-05	CbGpPWpGaD
